PHAT

Phathom Pharmaceuticals, Inc.

7.08 USD

Last updated Oct 9, 04:50 UTC

Yesterday HIGH

$7.03

Yesterday LOW

$6.64

52w HIGH

$18.31

52w LOW

$6.52

EPS

0.00

PE

0.00

Next Earnings

Oct 29, 2026

Overview News Government Trades Fundamentals

Phathom Pharmaceuticals, Inc. stock is down -18.34% since 30 days ago. The next earnings date is Oct 29, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 28.57% of the previous 7 October’s closed higher than September. 0% of analysts rate it a buy.

Benzinga Newsdesk

Thu Jul 30, 2026

Phathom Pharmaceuticals Lowers FY2026 Sales Guidance from $320.000M-$345.000M to $310.000M-$325.000M vs $332.196M Est

Phathom Pharmaceuticals (NASDAQ:PHAT) lowers FY2026 sales outlook from $320.000 million-$345.000 million to $310.000 million-$325.000 million vs $332.196 million estimate.
Benzinga Newsdesk

Thu Jul 30, 2026

Phathom Pharmaceuticals Q2 Sales $74.300M Beat $72.789M Estimate

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly sales of $74.300 million which beat the analyst consensus estimate of $72.789 million by 2.08 percent. This is a 88.09 percent increase over sales of $39.503
Benzinga Newsdesk

Tue Jun 23, 2026

Phathom Pharmaceuticals Completes Patient Enrollment In Its Phase 2 pHalcon-EoE-201 Clinical Study Of VOQUEZNA Tablets To Treat Eosinophilic Esophagitis In Adults

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced it has completed enrollment in its
Benzinga Newsdesk

Wed Jun 17, 2026

HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $26 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Phathom Pharmaceuticals (NASDAQ:PHAT) with a Buy and maintains $26 price target.
Benzinga Newsdesk

Thu Apr 30, 2026

Phathom Pharmaceuticals shares are trading lower. The company reported Q1 financial results.
Benzinga Insights

Thu Apr 30, 2026

Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
Benzinga Insights

Thu Apr 30, 2026

Earnings Scheduled For April 30, 2026
Benzinga Newsdesk

Thu Apr 30, 2026

Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $320.000M-$345.000M vs $331.417M Est

Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $320.000 million-$345.000 million to $320.000 million-$345.000 million vs $331.417 million estimate.
Benzinga Newsdesk

Thu Apr 30, 2026

Phathom Pharmaceuticals Q1 Adj. EPS $(0.18) Beats $(0.32) Estimate, Sales $58.301M Beat $57.028M Estimate

Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.32) by 43.75 percent. This is a 83.18 percent increase over losses of $(1.07) per
Benzinga Insights

Wed Apr 22, 2026

12 Health Care Stocks Moving In Wednesday's After-Market Session